Navigation Links
VI-Sense Test

ProductsVI-Sense Test
Company Common Sense
Item VI-Sense Test
Features 
  • Pale yellow strip which uses color identification
  • Lasts 48 hours after use except for urine stains
Description The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results.
Info 

Related medicine products :

1. Activa Therapy System
2. VISULAS 690s Photodynamic Therapy Laser System
3. VNS Therapy System
4. Cold Shoulder™ Therapy Wrap
5. InterStim Therapy -- Sacral Nerve Stimulation (SNS) for Urinary Control
6. Osbon ErecAid Vacuum Therapy System - Automatic
7. Osbon ErecAid Vacuum Therapy System - Manual
8. Osbon ErecAid Vacuum Therapy System - Classic
9. ErecAid® Esteem™ External Vacuum Therapy System
10. Sanford Guide to HIV/AIDS Therapy 2004
11. Sanford Guide to Antimicrobial Therapy 2005
TAG: Sense Test
The latest MAX MARA eyewear collection has evolved into a harmonious balance of tradition and,leading-edge trend, interpreting timeless themes in an absolutely modern way, yet never losing sight,
Inquire
Inquire
The collection features a range of 18 Ophthalmic frames created with the most modern materials and producted to the very hightest quality. The Optical collection includes several super lightweight Ti
Medicine Products:
(Date:5/15/2008)...nalysis for more than 25,000 foods and 10,000 ...simple, one-stop resource for counting carbohydrat...fe, the number-one diabetes,community resource, to...r,and Food Look-Up, the world,s largest and most c... tool for people with diabetes. Visit, http://www....
(Date:5/15/2008)...ta on worldwide cancer incidence, researchers at t...a, San Diego (UCSD) and the Department of Family a...ion between deficiency in exposure to sunlight, sp... , UVB exposure triggers photosynthesis of vita... available through diet and supplements. , Appr...
(Date:5/15/2008)...s enforcement action in Sierra acquisition was,ina...5 /PRNewswire-USNewswire/ -- The American Medical,...Clark County Medical,Society today announced they ...nal judgment proposed by the Department of Justice...s by United Health Group., The three physician or...
(Date:5/15/2008)...Newswire-USNewswire/ -- The US-China Business,Coun... continue to support,relief efforts under way in C...t hit Sichuan Province on May 12., USCBC member c...ars in,cash and in-kind goods and services for aid...atching funds for their employees., "The US-China...
Breaking Medicine News(10 mins):Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Physicians Charge Health Insurer Merger Not In The Public Interest 2Health News:US Companies Aid Chinese Earthquake Victims 2Health News:US Companies Aid Chinese Earthquake Victims 3Health News:US Companies Aid Chinese Earthquake Victims 4Health News:US Companies Aid Chinese Earthquake Victims 5Health News:US Companies Aid Chinese Earthquake Victims 6Health News:US Companies Aid Chinese Earthquake Victims 7
... people are affected by polio and as of now 15 peo...ct a three-day mass vaccination campaign to fight ...ibian dollars, said Kalumbi Shangula, permanent se...t 96 people have been affected by the outbreak in ...
...ere are now insisting on HIV tests ahead of marria...d an increase in the number of HIV tests, particul...me changed) got an HIV test done last year. "I w...her. But her parents thought I was a flirt," said ...
...esented at the 22nd annual conference of the Europ...n Prague, has found that many parents //are comfor...o fertilization. However the Iowa researchers fou...he risks of the process. "Along with many infertil...
...y by researchers from Duke University Medical Cent... blood transfusion into patient //who has undergon...se with raised death risks. Use of older blood al...for kidney problems,acute respiratory distress and...
Other Medicine News:Health News:Repeated Heart Surgery with Older Blood Transfusion Pack More Death Risk 2Health News:Repeated Heart Surgery with Older Blood Transfusion Pack More Death Risk 3
(Date:5/14/2008)...for cervical cancer prevention, GRAZ, Austria, Ma...tended follow-up study show that GlaxoSmithKline (...RVARIX(R) generates sustained high levels of,neutr...vical cancer-causing,human papillomavirus types fo... sustained neutralizing antibody levels observed a...
(Date:5/14/2008).../ -- Results of the PRoFESS(R),(Prevention Regimen... the,world,s largest clinical research study for s... at the XVII European Stroke Conference in Nice,F...for Aggrenox(R) and,clopidogrel were similar (9.0%...). The study did not meet its primary endpoint of ...
(Date:5/14/2008)...ocate to lead expansion of Cytel,s adapt...BRIDGE, Mass., May 14 /- Cytel Inc., ...es and specialized statistical software,today ann...resident,Adaptive Trials., Judith Quinlan brings...e Cytel team. Prior to joining Cytel Judith spent ...
(Date:5/14/2008)...irstCall/ -- Kosan Biosciences,Incorporated (Nasda...be,presented on tanespimycin, the company,s lead H...n with Herceptin(R) in patients with HER2-positive...ing of the American,Society of Clinical Oncology (... May 31 through June 3, 2008., Abstract 1027, tit...
Breaking Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6PRoFESS(R) Results Announced at XVII European Stroke Conference 2PRoFESS(R) Results Announced at XVII European Stroke Conference 3PRoFESS(R) Results Announced at XVII European Stroke Conference 4PRoFESS(R) Results Announced at XVII European Stroke Conference 5Judith Quinlan Joins Cytel as Vice President, Adaptive Trials 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3Winter Brings Pet Hazards 7495 1Winter Brings Pet Hazards 7495 2University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 1University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 2University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 3K State researchers findings on E coli 1444 1K State researchers findings on E coli 1444 2Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 1Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 2Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 3Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 4Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 5
... - Inovio Biomedical,Corporation (AMEX:INO), focus...r cancers and infectious diseases and a novel,alte...ounced today,that interim clinical trial results d...ed by Inovio,s electroporation technology was,safe...esulted in,significant objective tumor responses i...
..., 2007 - Cytos,Biotechnology AG (SWX:CYTN) reporte...blind combined phase I/IIa study with,CYT007-TNFQb...soriasis and other inflammatory conditions. The pr... and included 48 patients,suffering from moderate ... study, the safety and tolerability of ascending d...
Other Medicine Technology:Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4